Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App




ALDOA and FH4 Antibodies Associated with Cerebrovascular Disease

By LabMedica International staff writers
Posted on 28 Jul 2021
Ischemic stroke, including transient ischemic attack (TIA) and cerebral infarction (CI), is the most globally recognized cerebrovascular disorder, and is a serious health problem in the aging society. CI is an episode of neurological dysfunction caused by focal brain infarction, often resulting in fatality and disability. Patients with TIA are at a high risk of CI.

Endogenous antigens cause autoimmune responses that significantly influence the development of atherosclerosis, ultimately leading to the stenosis or blockage of the offending artery. These antigens induce autoantibodies that have been detected in the serum of patients with atherosclerosis-related diseases, such as CI, coronary heart disease (CHD), and diabetes mellitus (DM).

Clinical Biochemists and Geneticists at Chiba University (Chiba, Japan) collected serum samples from healthy donors (HDs) and patients diagnosed with TIA or CI caused by the development of atherosclerotic vulnerable plaque. In comparing the serum antibody levels, they set up four independent groups, which included 621 patients and 285 HDs. Of the 621 patients, 92, suffered from TIA, 464, from acute-phase cerebral infarction (aCI), and, 65, from old (chronic-phase) cerebral infarction (oCI). The serological identification of antigens by recombinant cDNA expression cloning (SEREX) is an established method for identifying endogenous antigenic proteins, combining molecular cloning and serological typing by using phage expression libraries.

In 19 patients with TIA, candidate antigens recognized by serum IgG autoantibodies were screened using a human aortic endothelial cell cDNA library. Through amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA, Perkin Elmer, Waltham, MA, USA), serum antibody levels against the candidate antigens were examined in the HDs, 92 TIA, and aCI, cohorts The plasma antibody levels in the Japan Public Health Center-based Prospective Cohort Study (1991–1993) were also examined. Glutathione-S-transferase (GST), GST–aldolase A (ALDOA), and GST–fumarate hydratase (FH) proteins were electrophoresed through SDS–polyacrylamide gel and analyzed by western blotting.

The team reported that in AlphaLISA, patients with TIA or aCI had significantly higher anti-ALDOA antibody (ALDOA-Ab) and anti-FH antibody (FH-Ab) levels than the HDs. In a multivariate logistic regression analysis, the ALDOA-Ab (odds ratio [OR]: 2.46) and FH-Ab (OR: 2.49) levels were independent predictors of TIA. According to the case–control study, the ALDOA-Ab (OR: 2.50) and FH-Ab (OR: 2.60) levels were associated with aCI risk. In a correlation analysis, both ALDOA-Abs and FH-Abs were well associated with hypertension, coronary heart disease, and habitual smoking. These antibody levels also correlated well with maximum intima–media thickness, which reflects atherosclerotic stenosis.

The authors concluded that the levels of antibodies against ALDOA and FH were significantly higher in patients with TIA or aCI than in HDs. These antibody markers can be novel predictors of TIA and pre-onset aCI, which are induced by atherosclerosis. The study was published on July 9, 2021 in the journal BMC Neurology.

Related Links:
Chiba University
Perkin Elmer



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.